BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 12190100)

  • 1. Interferon alfa-2b alone or combined with recombinant granulocyte-macrophage colony-stimulating factor as treatment of chronic hepatitis C.
    Grønbaek K; Krarup HB; Ring-Larsen H; Schaffalitzky de Muckadell O; Møller A; Schlichting P; Vyberg M
    Scand J Gastroenterol; 2002 Jul; 37(7):840-4. PubMed ID: 12190100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized controlled trial of recombinant human granulocyte-macrophage colony-stimulating factor for the treatment of chronic hepatitis c.
    Carreño V; Martín J; Pardo M; Brotons A; Anchía P; Navas S; Fernández M; Arocena C; Quiroga JA
    Cytokine; 2000 Feb; 12(2):165-70. PubMed ID: 10671303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of granulocyte macrophage colony stimulating factor alone or in combination with interferon-alpha-2b for treatment of chronic hepatitis C.
    Shiffman ML; Hofmann CM; Luketic VA; Sanyal AJ
    J Hepatol; 1998 Mar; 28(3):382-9. PubMed ID: 9551674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination treatment of interferon alpha-2b and ribavirin in comparison to interferon monotherapy in treatment of chronic hepatitis C genotype 4 patients.
    el-Zayadi A; Selim O; Haddad S; Simmonds P; Hamdy H; Badran HM; Shawky S
    Ital J Gastroenterol Hepatol; 1999; 31(6):472-5. PubMed ID: 10575565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc).
    Payen JL; Izopet J; Galindo-Migeot V; Lauwers-Cances V; Zarski JP; Seigneurin JM; Dussaix E; Voigt JJ; Selves J; Barange K; Puel J; Pascal JP
    Hepatology; 1998 Dec; 28(6):1680-6. PubMed ID: 9828235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of genotype 1b HCV-related chronic hepatitis: efficacy and toxicity of three different interferon alfa-2b/ribavirin combined regimens in naive patients.
    Scotto G; Fazio V; Palumbo E; Cibelli DC; Saracino A; Angarano G
    New Microbiol; 2005 Jan; 28(1):23-9. PubMed ID: 15782623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C relapsing after interferon monotherapy.
    Saracco G; Olivero A; Ciancio A; Carenzi S; Smedile A; Cariti G; Andreoni M; Orsi PG; Biglino A; Tabone M; Roffi L; Croce G; Manca A; Tappero G; Ciccone G; Rizzetto M
    Hepatology; 2002 Oct; 36(4 Pt 1):959-66. PubMed ID: 12297844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.
    McHutchison JG; Gordon SC; Schiff ER; Shiffman ML; Lee WM; Rustgi VK; Goodman ZD; Ling MH; Cort S; Albrecht JK
    N Engl J Med; 1998 Nov; 339(21):1485-92. PubMed ID: 9819446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial.
    Sostegni R; Ghisetti V; Pittaluga F; Marchiaro G; Rocca G; Borghesio E; Rizzetto M; Saracco G
    Hepatology; 1998 Aug; 28(2):341-6. PubMed ID: 9695995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Observation on the effect of GM-CSF and alpha-INF joint treatment on chronic hepatitis B].
    Shao C; Liu W; Chen X
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2001 Mar; 15(1):86-9. PubMed ID: 12526313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.
    Davis GL; Esteban-Mur R; Rustgi V; Hoefs J; Gordon SC; Trepo C; Shiffman ML; Zeuzem S; Craxi A; Ling MH; Albrecht J
    N Engl J Med; 1998 Nov; 339(21):1493-9. PubMed ID: 9819447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of high-dose interferon in combination with ribavirin in patients with chronic hepatitis C resistant to interferon alone.
    Min AD; Jones JL; Esposito S; Lebovics E; Jacobson IM; Klion FM; Goldman IS; Geders JM; Tobias H; Bodian C; Bodenheimer HC
    Am J Gastroenterol; 2001 Apr; 96(4):1143-9. PubMed ID: 11316161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
    Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
    Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial.
    Inoue K; Sekiyama K; Yamada M; Watanabe T; Yasuda H; Yoshiba M
    J Gastroenterol; 2003; 38(6):567-72. PubMed ID: 12825133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of ribavirin and interferon-alfa surpasses high doses of interferon-alfa alone in patients with genotype-1b-related chronic hepatitis C.
    Pol S; Nalpas B; Bourlière M; Couzigou P; Tran A; Abergel A; Zarski JP; Berthelot P; Bréchot C
    Hepatology; 2000 Jun; 31(6):1338-44. PubMed ID: 10827161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Durability of serological remission in chronic hepatitis C treated with interferon-alpha-2B.
    Sim H; Yim C; Krajden M; Heathcote J
    Am J Gastroenterol; 1998 Jan; 93(1):39-43. PubMed ID: 9448171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose interferon alpha-2b induction therapy in combination with ribavirin for Japanese patients infected with hepatitis C virus genotype 1b with a high baseline viral load.
    Tsubota A; Arase Y; Suzuki F; Suzuki Y; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kumada H
    J Gastroenterol; 2004; 39(2):155-61. PubMed ID: 15069622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study.
    Farrell GC; Bacon BR; Goldin RD
    Hepatology; 1998 Apr; 27(4):1121-7. PubMed ID: 9537453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response.
    Napoli N; Giannelli G; Antonaci A; Antonaci S
    J Viral Hepat; 2008 Apr; 15(4):300-4. PubMed ID: 18307592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia.
    Zeuzem S; Buti M; Ferenci P; Sperl J; Horsmans Y; Cianciara J; Ibranyi E; Weiland O; Noviello S; Brass C; Albrecht J
    J Hepatol; 2006 Jan; 44(1):97-103. PubMed ID: 16290907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.